An Impossible Balance: Antibiotic Resistance, Profits, and Public Health

DSpace/Manakin Repository

dc.contributor.advisor	Peter Hutt	en_US
dc.contributor.author	Barella, Nigel
dc.date.accessioned	2012-06-07T01:54:18Z
dc.date.issued	2011
dc.identifier.citation	Nigel Barella, An Impossible Balance: Antibiotic Resistance, Profits, and Public Health (May 2011)	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846728
dc.description.abstract	The scientific mechanism for the development of antibiotic resistance in microbes has long been understood, and has long cautioned against the use of low doses of antibiotics insufficient to treat disease thoroughly. Despite this, low doses of antibiotics have, for nearly half a century, been given to food animals to promote faster growth and greater feed efficiency. Though this raises public health concerns, a complex political landscape has historically prevented these public health concerns from dominating regulatory policy, and continues to do so. This paper examines the scientific, political, and legal issues associated with the use of antibiotics in animal agriculture, with particular focus on FDA’s historical and evolving role in regulating this issue, and concludes briefly with speculation about the future of this issue.	en_US
dash.license	LAA
dc.subject.other	Food and Drug Law	en_US
dc.title	An Impossible Balance: Antibiotic Resistance, Profits, and Public Health	en_US
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T01:54:18Z

Files	Size	Format	View
Barrella_Impossible_Balance[1].pdf	226.3Kb	PDF	View/Open